79 related articles for article (PubMed ID: 8243837)
1. Molecular forms of pseudocholinesterase in patients with Crohn's disease.
Novacek G; Vogelsang H; Maier-Dobersberger T; Kapiotis S; Lochs H; Gmeiner B
Digestion; 1993; 54(4):243-7. PubMed ID: 8243837
[TBL] [Abstract][Full Text] [Related]
2. Course of pseudocholinesterase isozymes during an acute phase in Crohn's disease.
Novacek G; Reinisch W; Vogelsang H; Kapiotis S; Gmeiner B
Digestion; 1996; 57(2):90-4. PubMed ID: 8786006
[TBL] [Abstract][Full Text] [Related]
3. Are single measurements of pseudocholinesterase and albumin markers for inflammatory activity or nutritional status in Crohn's disease?
Novacek G; Vogelsang H; Schmidt B; Lochs H
Wien Klin Wochenschr; 1993; 105(4):111-5. PubMed ID: 8451851
[TBL] [Abstract][Full Text] [Related]
4. The Fecal Microbiome in Quiescent Crohn's Disease with Persistent Gastrointestinal Symptoms Show Enrichment of Oral Microbes But Depletion of Butyrate and Indole Producers.
Golob J; Rao K; Berinstein J; Chey W; Owyang C; Kamada N; Higgins P; Young V; Bishu S; Lee A
medRxiv; 2023 May; ():. PubMed ID: 37292648
[TBL] [Abstract][Full Text] [Related]
5. Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease.
Maor I; Rainis T; Lanir A; Lavy A
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):598-602. PubMed ID: 21593678
[TBL] [Abstract][Full Text] [Related]
6. Pseudocholinesterase in Crohn's disease.
Guidetti-Sategna C; Bianco L; Durazzo M
Lancet; 1980 Sep; 2(8193):534. PubMed ID: 6105581
[No Abstract] [Full Text] [Related]
7. Low level of pseudocholinesterase in patient with Crohn's disease.
Khalil SN; Dudrick SJ; Mathieu A; Rigor BM; Fody EP
Lancet; 1980 Aug; 2(8188):267-8. PubMed ID: 6105432
[No Abstract] [Full Text] [Related]
8. Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease.
Vogelsang H; Hamwi A; Ferenci P
Digestion; 1996; 57(1):11-5. PubMed ID: 8626042
[TBL] [Abstract][Full Text] [Related]
9. Pseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children.
Mikecin L; Krizmaric M; Stepan Giljevic J; Gjurasin M; Kern J; Lenicek Krleza J; Popovic L
Croat Med J; 2013 Oct; 54(5):429-35. PubMed ID: 24170721
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between the functional activity and immunoreactive concentration of C1 esterase inhibitor in active and quiescent Crohn's disease.
Oshitani N; Kitano A; Nakamura S; Obata A; Hashimura H; Hiki M; Matsumoto T; Okawa K; Kobayashi K
Scand J Gastroenterol; 1988 Oct; 23(8):973-6. PubMed ID: 3201136
[TBL] [Abstract][Full Text] [Related]
11. Serum pseudocholinesterase and very-low-density lipoprotein metabolism.
Kutty KM; Payne RH
J Clin Lab Anal; 1994; 8(4):247-50. PubMed ID: 7931819
[TBL] [Abstract][Full Text] [Related]
12. [Decrease of fecal beta-galactosidase activity in Crohn disease].
Canva-Delcambre V; Soenen V; Mizon C; Cortot A; Mizon J; Colombel JF
Gastroenterol Clin Biol; 1993; 17(10):718-22. PubMed ID: 8288080
[TBL] [Abstract][Full Text] [Related]
13. Pseudocholinesterase levels in patients under electroconvulsive therapy.
Küçükosman G; Pişkin Ö; Hancı V; Okyay RD; Ayoğlu H; Yurtlu BS; Akın M; Turan IÖ
Saudi Med J; 2018 Jan; 39(1):103-106. PubMed ID: 29332117
[TBL] [Abstract][Full Text] [Related]
14. Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria.
Hvas CL; Kelsen J; Agnholt J; Höllsberg P; Tvede M; Møller JK; Dahlerup JF
Scand J Gastroenterol; 2007 May; 42(5):592-601. PubMed ID: 17454880
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse.
Reinisch W; Gasché C; Tillinger W; Wyatt J; Lichtenberger C; Willheim M; Dejaco C; Waldhör T; Bakos S; Vogelsang H; Gangl A; Lochs H
Am J Gastroenterol; 1999 Aug; 94(8):2156-64. PubMed ID: 10445543
[TBL] [Abstract][Full Text] [Related]
16. The influence of catecholamines on pseudocholinesterase enzymatic activity. Results of a laboratory investigation.
Ledowski T; Paech MJ; Clarke M; Schug SA
J Clin Monit Comput; 2006 Oct; 20(5):329-32. PubMed ID: 16953463
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment serum pseudocholinesterase level as a novel prognostic biomarker for upper tract urothelial carcinoma.
Zhang B; Shen C; Jin J; Song Y; Zhao Z; Zhang X; Wang G; Fan Y; Mi Y; Hu S; Cui Y; Zhou L; He Z; Yu W; Han W
Int Urol Nephrol; 2016 Dec; 48(12):1993-1999. PubMed ID: 27554671
[TBL] [Abstract][Full Text] [Related]
18. Serum measurements of pancreatitis associated protein in active Crohn's disease with ileal location.
Desjeux A; Barthet M; Barthellemy S; Dagorn JC; Hastier P; Heresbach D; Bernard JP; Grimaud JC
Gastroenterol Clin Biol; 2002 Jan; 26(1):23-8. PubMed ID: 11938036
[TBL] [Abstract][Full Text] [Related]
19. Serum lysozyme in Crohn's disease. A useful index of disease activity.
Falchuk KR; Perrotto JL; Isselbacher KJ
Gastroenterology; 1975 Oct; 69(4):893-6. PubMed ID: 1175883
[TBL] [Abstract][Full Text] [Related]
20. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
